Generic drug: bendamustine hydrochloride
Brand name: Treanda
What is Treanda (bendamustine hydrochloride), and how does it work?
Treanda (bendamustine hydrochloride) injection is an antineoplastic (anticancer) medication used to treat chronic lymphocytic leukemia. Treanda is also used to treat indolent B-cell non-Hodgkin lymphoma after other medications have been tried without successful treatment of this condition.
What are the side effects of Treanda?
Common side effects of Treanda include:
- nausea
- vomiting
- diarrhea
- tiredness
- weakness
- mouth sores
- constipation
- upset stomach
- swelling in your hands or feet
- headache
- dizziness
- drowsiness
- loss of appetite
- weight loss
- mild skin rash
What is the dosage for Treanda?
Selection Of Treanda Formulation To Administer
- Treanda is available in two formulations, a solution (Treanda Injection) and a lyophilized powder (Treanda for Injection).
- Do not use Treanda Injection if you intend to use closed system transfer devices (CSTDs), adapters and syringes containing polycarbonate or acrylonitrile-butadiene-styrene (ABS) prior to dilution in the infusion bag.
- If using a syringe to withdraw and transfer Treanda Injection from the vial into the infusion bag, only use a polypropylene syringe with a metal needle and polypropylene hub to withdraw and transfer Treanda Injection into the infusion bag. Polypropylene syringes are translucent in appearance.
- Treanda Injection and the reconstituted Treanda for Injection have different concentrations of bendamustine hydrochloride. The concentration of bendamustine hydrochloride in the solution is 90 mg/mL and the concentration of bendamustine hydrochloride in the reconstituted solution of lyophilized powder is 5 mg/mL. Do not mix or combine the two formulations.
- Treanda Injection must be withdrawn and transferred for dilution in a biosafety cabinet (BSC) or containment isolator using a polypropylene syringe with a metal needle and a polypropylene hub.
- If a CSTD or adapter that contains polycarbonate or ABS is used as supplemental protection prior to dilution , only use Treanda for Injection, the lyophilized powder formulation.
Dosing Instructions For CLL
Recommended Dosage
The recommended dose is 100 mg/m² administered intravenously over 30 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles.
Dose Delays, Dose Modifications And Reinitiation Of Therapy For CLL
- Delay Treanda administration in the event of Grade 4 hematologic toxicity or clinically significant ≥ Grade 2 nonhematologic toxicity. Once non-hematologic toxicity has recovered to less than or equal to Grade 1 and/or the blood counts have improved [Absolute Neutrophil Count (ANC) ≥ 1 x 109/L, platelets ≥ 75 x 109/L], reinitiate Treanda at the discretion of the treating physician. In addition, consider dose reduction.
- Dose modifications for hematologic toxicity: for Grade 3 or greater toxicity, reduce the dose to 50 mg/m² on Days 1 and 2 of each cycle; if Grade 3 or greater toxicity recurs, reduce the dose to 25 mg/m² on Days 1 and 2 of each cycle.
- Dose modifications for non-hematologic toxicity: for clinically significant Grade 3 or greater toxicity, reduce the dose to 50 mg/m² on Days 1 and 2 of each cycle.
- Consider dose re-escalation in subsequent cycles at the discretion of the treating physician.
Dosing Instructions For NHL
Recommended Dosage
The recommended dose is 120 mg/m² administered intravenously over 60 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles.
Dose Delays, Dose Modifications And Reinitiation Of Therapy For NHL
- Delay Treanda administration in the event of a Grade 4 hematologic toxicity or clinically significant greater than or equal to Grade 2 non-hematologic toxicity. Once non-hematologic toxicity has recovered to ≤ Grade 1 and/or the blood counts have improved [Absolute Neutrophil Count (ANC) ≥ 1 x 109/L, platelets ≥ 75 x 109/L], reinitiate Treanda at the discretion of the treating physician. In addition, consider dose reduction.
- Dose modifications for hematologic toxicity: for Grade 4 toxicity, reduce the dose to 90 mg/m² on Days 1 and 2 of each cycle; if Grade 4 toxicity recurs, reduce the dose to 60 mg/m² on Days 1 and 2 of each cycle.
- Dose modifications for non-hematologic toxicity: for Grade 3 or greater toxicity, reduce the dose to 90 mg/m² on Days 1 and 2 of each cycle; if Grade 3 or greater toxicity recurs, reduce the dose to 60 mg/m² on Days 1 and 2 of each cycle.

QUESTION
What is leukemia? See AnswerWhat drugs interact with Treanda?
Effect Of Other Drugs On Treanda
CYP1A2 Inhibitors
- The coadministration of Treanda with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Treanda.
- Consider alternative therapies that are not CYP1A2 inhibitors during treatment with Treanda.
CYP1A2 Inducers
- The coadministration of Treanda with CYP1A2 inducers may decrease bendamustine plasma concentrations and may result in decreased efficacy of Treanda.
- Consider alternative therapies that are not CYP1A2 inducers during treatment with Treanda.
Is Treanda safe to use while pregnant or breastfeeding?
- Advise pregnant women and females of reproductive potential of the potential risk to a fetus.
- Advise females to inform their healthcare provider of a known or suspected pregnancy.
- Advise female patients of reproductive potential to use effective contraception during treatment with Treanda and for at least 6 months after the final dose.
- Males with female partners of reproductive potential should use effective contraception during treatment with Treanda and for at least 3 months after the final dose.
- Females should not breastfeed during treatment with Treanda and for at least 1 week after the final dose.
Summary
Treanda (bendamustine hydrochloride) injection is an antineoplastic (anticancer) medication used to treat chronic lymphocytic leukemia. Treanda is also used to treat indolent B-cell non-Hodgkin lymphoma after other medications have been tried without successful treatment of this condition. Common side effects of Treanda include nausea, vomiting, diarrhea, tiredness, weakness, mouth sores, constipation, upset stomach, swelling in your hands or feet, headache, dizziness, drowsiness, loss of appetite, weight loss, and mild skin rash.
Multimedia: Slideshows, Images & Quizzes
-
Cancer: Guide to Leukemia
Learn about the common types and stages of leukemia, who gets it, symptoms, tests, treatments, and more. People with blood cancer...
-
Blood Cancer Types: Leukemia, Lymphomas, Myelomas, and More
Types of blood cancers include leukemia, lymphomas, multiple myelomas, and others discussed in this slideshow. Symptoms may...
-
Leukemia Quiz
What do you know about leukemia? Did you know there are different types? What are the symptoms? Take the Leukemia Quiz and test...
Related Disease Conditions
-
Leukemia
Leukemia is a type of cancer of the blood cells in which the growth and development of the blood cells are abnormal. Strictly speaking, leukemia should refer only to cancer of the white blood cells (the leukocytes) but in practice, it can apply to malignancy of any cellular element in the blood or bone marrow, as in red cell leukemia (erythroleukemia).
-
What Is the Life Expectancy of a Person With Leukemia?
Leukemia is a group of cancers of the blood affecting the white blood cells. White blood cells are the infection-fighting cells of the body. In adults, leukemia is most common in people older than 55 years, with the average age of diagnosis being 66 years. It is also one of the most common cancers in children and adults younger than 20 years. The survival rate is higher for younger people.
-
How Does Leukemia Kill?
Leukemia is a cancer of the white blood cells of the bone marrow. Patients with leukemia have an over-production of a particular blood cell type in the body, the white blood cells (cells that fight infection, and provide immunity).
-
What Is Non-Hodgkin's Lymphoma?
Non-Hodgkin's lymphoma (NHL) is cancer of the lymphatic system, a vital part of the body's immune system. Symptoms include swollen lymph nodes, fever, night sweats, coughing, weakness, chest pain, unexplained weight loss, and abdominal pain.
-
Can Lymphoma Be Completely Cured?
Lymphomas are considered to be a treatable form of cancer if detected early. The overall 5-year survival rate for non-Hodgkin lymphoma (NHL) is 62%, whereas the 5-year survival rate for Hodgkin lymphoma is 92% if detected early.
-
Mantle Cell Lymphoma (MCL)
Mantle cell lymphoma (MCL) is a rare form of non-Hodgkin's lymphoma. It is not known what causes MCL. MCL signs and symptoms include fever, enlarged spleen and liver, fatigue, and weight loss. Treatment of MCL incorporates radiotherapy and chemotherapy. MCL has a poor prognosis as it typically is diagnosed in a late stage.
-
Survival Rate for Acute Lymphoblastic Leukemia
The prognosis depends on the type of leukemia, the extent of the disease, age of the patient, and the general condition of the patient. Some patients can go into complete remission. The average five-year survival rate of leukemia is 60-65%.
-
What Is Burkitt Lymphoma?
There are multiple types of Burkitt lymphoma. Burkitt lymphomas are types of non-Hodgkin's lymphoma that affect the bone marrow and central nervous system. Symptoms of Burkitt lymphoma may include nausea, vomiting, headache, fatigue, enlarged lymph nodes, and many other symptoms. Diagnosis involves lab testing, imaging studies, patient history, and cytogenic evaluation. There are multiple staging systems used to stage Burkitt lymphoma. Treatment consists of chemotherapy. The prognosis tends to be more favorable in children than in adults.
-
Hodgkin's vs. Non-Hodgkin's Lymphoma
Both Hodgkin's disease (sometimes referred to as Hodgkin's lymphoma) and non-Hodgkin's lymphoma are cancers that originate in a type of white blood cell known as a lymphocyte, an important component of the body's immune system.
-
What Is the Main Cause of Primary Lymphoma of Bone?
Primary lymphoma of bone (PLB) is a rare type of cancer that starts in the bone instead of the lymph nodes. PLB accounts for less than 5% of all bone tumors. PLB is also known as reticulum cell sarcoma, malignant lymphoma of bone or osteolymphoma, and it is a type of non-Hodgkin’s lymphoma. Pain is the most common symptom of PLB.
-
How Bad Is Lymphoma Cancer Of Bone?
Lymphoma is a cancer of infection-fighting cells (lymphocytes), white blood cells of the immune system. These cells are normally found in the lymph nodes, spleen, thymus, and bone marrow.
-
Leukemia: Signs, Symptoms, And Complications
Leukemia results when the genetic material (DNA) of a single cell in the bone marrow transforms, this is called a mutation. A mutated cell does not perform body function, but it eats away the nutrition meant for the normal cells.
-
How Do You Get Non-Hodgkin’s Lymphoma?
Non-Hodgkin lymphoma (NHL) is cancer that affects the lymphatic system, a part of the body’s immune system. The lymphatic system helps in filtering foreign cells and microorganisms. The lymphatic system is comprised of lymph fluid, lymph nodes, tonsils, thymus, and the spleen.
-
What Are the Stages of Chronic Lymphocytic Leukemia?
Chronic lymphocytic leukemia is a cancer of the blood and bone marrow. With this type of cancer, the marrow creates too many abnormal lymphocytes. There are five stages of chronic lymphocytic leukemia.
Treatment & Diagnosis
- Leukemia FAQs
- Evolution of Treatment for a Rare Type of Leukemia
- Gleevec and Chronic Myeloid Leukemia
- How Familes Cope with a Leukemia Diagnosis
- Coping with a Bad Disease - Community Counts
- A Family's Leukemia Diary - Coping
- Is Multiple Myeloma the Same as Leukemia?
- Does Folic Acid Prevent Leukemia?
- Can Folic Acid Prevent Leukemia?
- Chronic Myelogenous Leukemia (CML)
Medications & Supplements

Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.